Bevacizumab: all 1,786 studies that test it

Page 11 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialActive, not recruitingNCT04727307Phase 2
• Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaStatus unknownNCT04725448Phase 2
• Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaActive, not recruitingNCT04724239Phase 2
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2
• Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal CancerStatus unknownNCT04683965Phase 2
• Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionStatus unknownNCT04682210Phase 3
• Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and BevacizumabTerminatedNCT04681677Phase 2
• Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic RetinopathyCompletedNCT04674254Phase 4
• An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedNCT04660812Phase 1/2
• Bevacizumab Treatment For Type 1 ROPActive, not recruitingNCT04634578Phase 2
• HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular CarcinamaStatus unknownNCT04627363Phase 2
• Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.Status unknownNCT04601701Not applicable
• Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.Status unknownNCT04601688Not applicable
• Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCActive, not recruitingNCT04587128Phase 2
• Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.Active, not recruitingNCT04564898Phase 1/2
• An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)Active, not recruitingNCT04563338Phase 2
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersTerminatedNCT04553692Phase 1
• Treatment of Bevacizumab Followed by Steroid in RNStatus unknownNCT04553510Phase 2
• QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal CancerStatus unknownNCT04527068Phase 2
• Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver MetastasesStatus unknownNCT04525326Phase 3
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingNCT04524871Phase 1/2
• Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerWithdrawnNCT04510584Phase 2
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerWithdrawnNCT04466917Phase 3
• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCCWithdrawnNCT04465734Phase 3
• Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM PatientsCompletedNCT04446416Not applicable
• Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2
• First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCCompletedNCT04408118Phase 2
• Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLCStatus unknownNCT04405674Phase 2
• Bevacizumab In Hereditary Hemorrhagic TelangiectasiaActive, not recruitingNCT04404881Phase 2
• Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaCompletedNCT04393220Phase 2
• Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory GlioblastomaCompletedNCT04385173Phase 1
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaActive, not recruitingNCT04356729Phase 2
• Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 CohortStatus unknownNCT04344782Phase 2
• Bevacizumab in Patients With Severe Covid-19Status unknownNCT04305106Phase 3
• A Phase II Study of Triple-negative Breast Cancer Brain Metastases.Status unknownNCT04303988Phase 2
• Bevacizumab in Severe or Critical Patients With COVID-19 PneumoniaCompletedNCT04275414Phase 2
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingNCT04262466Phase 1/2
• Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLCCompletedNCT04238169Phase 2
• Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCActive, not recruitingNCT04227028Phase 1
• A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal CancerActive, not recruitingNCT04188145Phase 3
• Atezolizumab Plus Bevacizumab With HCC and HBV InfectionActive, not recruitingNCT04180072Not applicable
• Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.Status unknownNCT04178057Phase 1
• Bevacizumab and Tocotrienol in Recurrent Ovarian CancerCompletedNCT04175470Phase 2
• Clinical Trial in Chinese Healthy Volunteers of GB222Status unknownNCT04175158Phase 1
• Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without BevacizumabCompletedNCT04164069Phase 1
• Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04148898Phase 2
• A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.CompletedNCT04147351Phase 2
• A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical CancerStatus unknownNCT04138992Phase 2/3
• A Study Comparing SIBP-04 and Bevacizumab in Healthy Male SubjectsCompletedNCT04135898Phase 1
• A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERSWithdrawnNCT04126044Phase 1
• The Sahlgrenska Anti-VEGF StudyActive, not recruitingNCT04101877Phase 2
• Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6TerminatedNCT04074785Early Phase 1
• Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT04072679Phase 1
• Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm PatientsCompletedNCT04072198Phase 2
• Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract SurgeryWithdrawnNCT04067856Not applicable
• Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Active, not recruitingNCT04017455Phase 2
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant AscitesStatus unknownNCT03990103Phase 2
• A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT03973112Phase 2
• A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03952403Phase 3
• Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)Status unknownNCT03912402Phase 2
• Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver GeneStatus unknownNCT03905317Phase 2
• Bevacizumab After Chemoradiotherapy For Locally Advanced Lung AdenocarcinomaCompletedNCT03904563Phase 2
• Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)Active, not recruitingNCT03896074Phase 2
• Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent GlioblastomaCompletedNCT03890952Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
• A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03844074Phase 3
• Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal CancerWithdrawnNCT03843853Phase 2
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial CancerWithdrawnNCT03836157Phase 2
• QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.Active, not recruitingNCT03828227Phase 3
• Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckCompletedNCT03818061Phase 2
• Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPCActive, not recruitingNCT03813394Phase 1/2
• Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3
• Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3
• A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Status unknownNCT03794440Phase 2/3
• Alectinib in Combination With Bevacizumab in ALK Positive NSCLCCompletedNCT03779191Phase 2
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
• A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsStatus unknownNCT03757936Phase 1
• A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic SyndromesCompletedNCT03746041Phase 1
• The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver MetastasesStatus unknownNCT03711240Phase 2
• Treatment of Colorectal Liver Metastases With Immunotherapy and BevacizumabCompletedNCT03698461Phase 2
• A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaWithdrawnNCT03693573Phase 3
• Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian CancerTerminatedNCT03690739Phase 3
• Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)CompletedNCT03668054Phase 3
• A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCTerminatedNCT03666728Phase 2
• Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®CompletedNCT03659305Phase 1
• Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsStatus unknownNCT03647956Phase 2
• SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerTerminatedNCT03645876Phase 2
• Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal CancerActive, not recruitingNCT03635021Phase 3
• Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent GlioblastomaStatus unknownNCT03631836Phase 1
• Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLCStatus unknownNCT03616691Phase 2
• Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian CancerStatus unknownNCT03611179Phase 2
• Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical TrialStatus unknownNCT03609307Phase 2/3
• A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesStatus unknownNCT03607643Phase 1/2
• Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1
• Effect of Bevacizumab in Metastatic Triple Negative Breast CancerCompletedNCT03577743Phase 2
• Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab TreatmentTerminatedNCT03573986Phase 1
• QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2

← Bevacizumab overview